All News

heart.jpg (keep)

CV risk factors not equal when considering magnitude of risk

Janet Pope, MD, MPH, FRCPC

What can we learn from Oral Surveillance?



The Oral Surveillance trial has almost become a household word for rheumatologists.

Read Article
computer screen safety

The Safety of Rituximab and JAK Inhibitors with post-COVID Vaccination

Md Yuzaiful Md Yusof, MRCP(UK), PhD

At the onset of the pandemic, data from the Global Rheumatology Alliance reported increased risk of poor severe COVID outcomes including deaths in patients who were treated with rituximab and baricitinib. With the vaccination program undertaken globally, has this risk been attenuated?

Read Article
guidelines.recommendations.jpg

BSR Guideline for Psoriatic Arthritis - 2022 Update

Jack Cush, MD

The British Society of Rheumatology has published their updated 2022 recommendations for the use of biologics and targeted synthetic treatments in patients with psoriatic arthritis. These guidelines follow initial treatment with a single conventional systemic disease-modifying anti-rheumatic drug, typically methotrexate typically. They noted that up to 50% of people with PsA require biologic or targeted synthetic (b/ts)DMARD therapy. 

Read Article
Malar,rash,SLE, Lupus

Emerging Therapeutics for Lupus

Kathryn H. Dao, M.D.

Impressive data on novel treatment for SLE were presented at the EULAR22 Congress. A disease that is difficult to study due to its pleomorphic presentation, unpredictable disease course, and high mortality rates, SLE is considered the dragon of all autoimmune diseases. Here are highlights of four exciting abstracts presented at the meeting with emerging therapeutics designed to slay the beast. 

Read Article
exhibitor.floor.ACR

EULAR 2022 – Day 4 Report

Jack Cush, MD

Bags are packed, ready to go, but wait there’s more abstracts to show.



The big news today were the “late breaking” abstracts. This is usually a favorite session of many as this is where the newest of study data often is showcased. 

Read Article
cancer search news magnify

Malignancy risk on b/tsDMARDs in patients with prior malignancy history

Eric Dein, MD

For autoimmune patients with a history of malignancy, the initiation of biologic or targeted synthetic disease modifying agents (bDMARD/tsDMARDs) may provoke concern.

Read Article
PSA2L.jpg

Key Psoriatic Arthritis topics and updates at EULAR 2022

Antoni Chan, MD, PhD

At EULAR 2022, I have been looking at topics and presentations in psoriatic arthritis (PsA).  Here are my top picks from this year's meeting.

Read Article
#LB0004 #EULAR2022 Positive Phase 2 results in #lupus! Deucravacitinib, a TYK2-inhibitor reported significantly more SRI-4 response rates in DEUC vs PBO. PBO: 34.4%; DEUC 3 mg BID:58.2%, DEUC 6 mg BID:49.5%, DEUC 12 mg QD:44.9%. No major safety. Will proceed to Phase 3 @RheumNow https://t.co/cZLv6bbHer
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
Baricitinib (JAK1/2 inhib) in 10 pts w/ systemic sclerosis showed improvement in modified Rodnan Skin Score ( −11.67 @wk 24; p=0.0008); 3/4 w/ digital ulcers healed at week 24. Similar findings seen in bleomycin induced animal model https://t.co/1G9CGjLK2N https://t.co/Gt35DcMyuz

Links:

Dr. John Cush RheumNow ( View Tweet)
EULAR recommendations for management of #RheumatoidArthritis 6️⃣Glucocorticoids should be tapered & discontinued as soon as clinically feasible 8️⃣JAKi can be used but consider risk factors via Prof Smolen #EULAR2022 https://t.co/7cocPSpgkH
Dr Ai Lyn Tan DrAiLynTan ( View Tweet)
#ClinicalPearl Oral Surveillance chance of having a MACE was highest....you guessed it, in those with past MACE events. Some CV risks have different risks ex HTN May have less risk vs high cholesterol @RheumNow @eular_org #EULAR2022 POS0237 https://t.co/kTn4rxMlej
Janet Pope Janetbirdope ( View Tweet)
Deucravacitinib: TYK2 inhibitor in pts with active SLE Phase 2, randomized, double blind, placebo-controlled study Met primary endpoint SRI response across all doses No death, MACE, VTE, systemic infections @RheumNow #EULAR2022 ABST#LB0004 https://t.co/yAM8qUZgee
Robert B Chao, MD doctorRBC ( View Tweet)
Post-ORAL Surveillance, the @eular_org RA treatment guidelines had to change. In the 2022 version: JAKi now separate sentence following bDMARDs, with proviso to mention risk. Sometimes guidelines have to tell us what we’ve all inevitably been expecting #EULAR2022 @RheumNow https://t.co/RPbPNi3vcW
David Liew drdavidliew ( View Tweet)
In vitro study shows Upadacitinib inhibits enthesis T cell derived TNFa and IL-17A, disrupting the prominent IL-23/IL-17/TNFa axis driving SpA. @RheumNow #EULAR2022 ABST#POS0331 https://t.co/pNL3Zlgmt7
Robert B Chao, MD doctorRBC ( View Tweet)
#OP0236 #EULAR2022 Prof Schulze-Koops highlighted a mechanistic study that baricitinib therapy ex vivo suppressed autophagy, increased apoptosis, and reduced expression of adhesion molecules in #sjogren salivary glands. Next step should be randomised controlled trial @RheumNow https://t.co/dirmHY9cYJ
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
Tofacitinib had faster and larger impact on improvement of fatigue compared to placebo in treatment of ankylosing spondylitis pts. Note 100% fatigue resolution roughly same vs. placebo @RheumNow #EULAR2022 ABST#POS0305 https://t.co/Doep91QIRa
Robert B Chao, MD doctorRBC ( View Tweet)
Upadacitinib effective in treatment of ankylosing spondylitis pts refractory to biologic tx - phase 3 trial Primary endpoint (ASAS40) and secondary endpoints met No malignancy, MACE, VTE, death @RheumNow #EULAR2022 ABST#POS0306 https://t.co/UL4hUJ0rQV
Robert B Chao, MD doctorRBC ( View Tweet)
#LB0002 #EULAR2022 An interesting study design looking at flare rate following withdrawal of drug after WK12. Phase 3 RCT of Baricitinib in paediatric JIA showed 76% met ACR30 at WK12. The Double-blind withdrawal showed less patients on Bari flared vs PBO (17% vs 51%) @RheumNow https://t.co/T0mSDkoHJo
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
Ramanan et al Baricitinib in JIA. Double blind withdrawal study of prior responders. Earlier flare with PBO vs bari (HR 0.24 [95%CI 0.13,0.45], p<0.001. Less flares with bari vs PBO (17.1% vs 50.6%) p<0.001 @RheumNow #EULAR2022 LB0002 https://t.co/22rp70njRu https://t.co/LtJE9dz0GT

Links:

Richard Conway RichardPAConway ( View Tweet)
#EULAR2022 LB002 P3 Double-Blind W/d study: Baricitinib for JIA ⭐️All pts start in open label w good benefit (1/2 with ACR70) ⭐️PBO W/d led to 50% flare vs 17% in BARI group, flares earlier @RheumNow https://t.co/apSSLqu1mp
Eric Dein ericdeinmd ( View Tweet)
How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×